Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Malaria Vaccine R&D Gets Funding

by Lisa M. Jarvis
August 3, 2009 | A version of this story appeared in Volume 87, Issue 31

Dutch biopharmaceutical firm Crucell will collaborate with the PATH Malaria Vaccine Initiative (MVI) and the U.S. Agency for International Development (USAID) in an effort to bolster the immune response to a malaria vaccine in development. Crucell will use its recombinant adenoviruses, or viruses associated with the common cold, to deliver a malaria antigen to the immune system. USAID will fund the project. MVI has also expanded an existing contract with GenVec, awarding the Gaithersburg, Md.-based biotech firm $2 million to support preclinical studies of its adenovirus-based vaccines. Separately, NIH has awarded GenVec a $600,000 Small Business Innovation Research grant to support its malaria vaccine program.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.